Kyogo Itoh

Summary

Affiliation: Kurume University School of Medicine
Country: Japan

Publications

  1. pmc UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour
    N Tsuda
    Department of Immunology, Kurume University School of Medicine, 67 Asohi machi, Kurume, Fukuoka 830 0011, Japan
    Br J Cancer 87:1006-12. 2002
  2. doi request reprint Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination
    Kanako Iseki
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka, Japan
    Cancer Sci 101:2110-4. 2010
  3. ncbi request reprint Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic anaphylaxis
    Akira Yamada
    Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, and Center of the 21st Century Center of Excellence Program for Medical Science, Kurume University, Kurume, Japan
    J Immunol 176:857-63. 2006
  4. ncbi request reprint Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes
    A Yamada
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume 830 0011, Japan
    Cancer Res 61:6459-66. 2001
  5. ncbi request reprint Analysis of cellular localization of SART3 tumor antigen by a newly established monoclonal antibody: heterotopic expression of SART3 on the surface of B-lineage leukemic cells
    M Koga
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka 830 0011, Japan
    Oncol Rep 11:785-9. 2004
  6. ncbi request reprint Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer
    A Yamada
    Kurume University Research Center for Innovative Cancer Therapy, and Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Cancer Immunol Immunother 48:147-52. 1999
  7. ncbi request reprint Molecular cloning of a glycosylphosphatidylinositol-anchored molecule CDw108
    A Yamada
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Department of Immunology, Japan
    J Immunol 162:4094-100. 1999
  8. ncbi request reprint Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients
    Koichi Azuma
    Department of Immunology and Research Center of Innovative Cancer Therapy of the 21st Century Center of Excellence Program for Medical Science, Kurume University School of Medicine, Kurume, Japan
    Clin Cancer Res 10:6695-702. 2004
  9. ncbi request reprint Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients
    Hiroko Takedatsu
    Department of Immunology, Kurume University, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Clin Cancer Res 10:1112-20. 2004
  10. ncbi request reprint Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles
    Elnisr Rashed Mohamed
    Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 34:529-36. 2009

Collaborators

Detail Information

Publications139 found, 100 shown here

  1. pmc UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour
    N Tsuda
    Department of Immunology, Kurume University School of Medicine, 67 Asohi machi, Kurume, Fukuoka 830 0011, Japan
    Br J Cancer 87:1006-12. 2002
    ..These peptides may be useful in the peptide-based specific immunotherapy for patients with malignant brain tumours...
  2. doi request reprint Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination
    Kanako Iseki
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka, Japan
    Cancer Sci 101:2110-4. 2010
    ....
  3. ncbi request reprint Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic anaphylaxis
    Akira Yamada
    Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, and Center of the 21st Century Center of Excellence Program for Medical Science, Kurume University, Kurume, Japan
    J Immunol 176:857-63. 2006
    ....
  4. ncbi request reprint Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes
    A Yamada
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume 830 0011, Japan
    Cancer Res 61:6459-66. 2001
    ....
  5. ncbi request reprint Analysis of cellular localization of SART3 tumor antigen by a newly established monoclonal antibody: heterotopic expression of SART3 on the surface of B-lineage leukemic cells
    M Koga
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka 830 0011, Japan
    Oncol Rep 11:785-9. 2004
    ..These results suggest that heterotopically expressed SART3 is a tumor-associated antigen rather than a differentiation antigen on B-lineage cells...
  6. ncbi request reprint Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer
    A Yamada
    Kurume University Research Center for Innovative Cancer Therapy, and Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Cancer Immunol Immunother 48:147-52. 1999
    ..The HLA-A2-restricted CTL recognized the SART-1, but not the MAGE-1 or MAGE-3 antigen. These results may facilitate a better understanding of the molecular basis of tumor-specific immunity at the tumor site of ovarian cancer...
  7. ncbi request reprint Molecular cloning of a glycosylphosphatidylinositol-anchored molecule CDw108
    A Yamada
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Department of Immunology, Japan
    J Immunol 162:4094-100. 1999
    ..Radiation hybrid mapping indicated that the CDw108 gene was located in the middle of the long arm of chromosome 15 (15q23-24). This molecular information will be critical for understanding the biological function of the CDw108 Ag...
  8. ncbi request reprint Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients
    Koichi Azuma
    Department of Immunology and Research Center of Innovative Cancer Therapy of the 21st Century Center of Excellence Program for Medical Science, Kurume University School of Medicine, Kurume, Japan
    Clin Cancer Res 10:6695-702. 2004
    ....
  9. ncbi request reprint Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients
    Hiroko Takedatsu
    Department of Immunology, Kurume University, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Clin Cancer Res 10:1112-20. 2004
    ..This study tried to identify CTL epitope peptides as vaccine candidates sharing by HLA-A3(+), -A11(+), -A31(+), and -A33(+) cancer patients...
  10. ncbi request reprint Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles
    Elnisr Rashed Mohamed
    Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 34:529-36. 2009
    ..These results suggest that this peptide can be applicable as a cancer vaccine not only for HLA-A24+, but also for HLA-A11+, HLA-A31+ and HLA-A33+ prostate cancer patients...
  11. ncbi request reprint Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Oncol Res 16:341-9. 2007
    ..0347, odds ratio 2.569) were independent predictors of disease death. These encouraging results show the need for further evaluation of the combination of personalized peptide vaccination and low dose of EMP for metastatic HRPC patients...
  12. ncbi request reprint Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles
    Satoko Matsueda
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Clin Cancer Res 11:6933-43. 2005
    ..In this study, we attempted to identify CTL-directed peptide candidates, derived from prostate-related antigens and shared by HLA-A11+, HLA-A31+, and HLA-A33+ prostate cancer patients...
  13. ncbi request reprint Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types
    Yoshimi Arima
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 27:981-8. 2005
    ..These findings indicate that PTH-rP could be a common target molecule in specific immunotherapy for patients with a wide variety of tumor types, particularly bone metastases...
  14. ncbi request reprint Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432
    Takeharu Ono
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan
    Clin Cancer Res 12:1325-32. 2006
    ....
  15. doi request reprint Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles
    Shigeru Yutani
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer Sci 100:1935-42. 2009
    ..Because of its tolerability and higher rate of immune boosting, this protocol is recommended for a phase II study to investigate its clinical efficacy...
  16. ncbi request reprint Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma
    Yi Wang
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan
    J Immunother 28:535-41. 2005
    ..These findings indicate that PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers...
  17. ncbi request reprint Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients
    Hiroko Takedatsu
    Department of Immunology, Kurume University School of Medicine, Kurume, Japan
    Int J Oncol 24:337-47. 2004
    ..These peptides might be useful for the development of a peptide-based immunotherapy for HLA-A31+ cancer patients...
  18. ncbi request reprint Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient
    Mamoru Harada
    Department of Immunology, Kurume University of School of Medicine, Fukuoka 830 0011, Japan
    J Immunother 28:368-75. 2005
    ..These findings indicate that vaccination with CTL-directed peptides, including a PSA-derived peptide, was able to elicit and spread humoral and TH1-type immune responses to the PSA protein...
  19. ncbi request reprint Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients
    Mamoru Harada
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Oncol Rep 12:601-7. 2004
    ..These results indicate that these PSMA441-450 and PAP112-120 peptides could be promising candidates for peptide-based immunotherapy for HLA-A2(+) prostate cancer...
  20. ncbi request reprint Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer
    Satoko Matsueda
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, 830 0011 Fukuoka, Japan
    Cancer Immunol Immunother 53:479-89. 2004
    ....
  21. ncbi request reprint Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients
    Shigenori Homma
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 29:577-87. 2006
    ..Two newly identified SCCA-derived peptides with the ability to induce CTL activity in both SCC and non-SCC cancer patients may be applicable to specific immunotherapy for HLA-A24+ cancer patients with SCC, but not those with non-SCC...
  22. ncbi request reprint Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 29:1555-60. 2006
    ..IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients...
  23. ncbi request reprint New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles
    Satoko Matsueda
    Department of Immunology, Karume University School of Medicine, Karume, Fukuoka, Japan
    J Immunother 30:274-81. 2007
    ..This information could expand the chance of a peptide-based cancer vaccine for epithelial cancer patients of many ethnic populations...
  24. ncbi request reprint HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
    Oncol Rep 18:1463-8. 2007
    ..These results indicate that HLA-G-associated immunoregulation can be overcome and that HLA-G peptide-based anti-cancer immunotherapy is feasible...
  25. ncbi request reprint Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery
    Shoko Tanaka
    Department of Dermatology, Kurume University of School of Medicine, Fukuoka, Japan
    J Immunother 26:357-66. 2003
    ..These results indicate that peptide vaccination of patients showing evidence of pre-existing peptide-specific CTL precursors can be applied in further clinical trials aimed at the treatment of melanoma and other types of cancer...
  26. ncbi request reprint Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Asahi machi, Kurume, Japan
    Prostate 60:32-45. 2004
    ..Additive antitumor effects could be achieved by combination of immunotherapy and cytotoxic agents with no or minimum suppression...
  27. doi request reprint A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles
    Yamei Niu
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
    J Med Virol 81:1232-40. 2009
    ..These results may provide new insights for the development of a novel peptide vaccine against HCV compatible with various HLA class IA types...
  28. ncbi request reprint Identification of target antigens in specific immunotherapy for renal cell carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University, Fukuoka, Japan
    J Urol 177:1157-62. 2007
    ....
  29. ncbi request reprint Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer
    Shigeki Shichijo
    Department of Immunology, Kurume University School of Medicine, Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University, Kurume, Fukuoka, Japan
    Clin Cancer Res 10:5828-36. 2004
    ..The purpose of this work was to provide a scientific basis for specific immunotherapy of colon cancer...
  30. ncbi request reprint Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients
    Masahiro Tanaka
    Department of Immunology, Kurume University School of Medicine, Kurume 830 0011, Japan
    Oncol Rep 18:161-6. 2007
    ....
  31. ncbi request reprint A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients
    Shigeru Yutani
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Oncol Rep 30:1094-100. 2013
    ..Due to the safety profile and the potential clinical efficacy, the conduction of additional clinical trials of PPV for chemotherapy-resistant advanced pancreatic cancer patients is warranted...
  32. doi request reprint Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients
    Mingyue Jin
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Fukuoka 830 0011, Japan
    Cancer Sci 99:1656-62. 2008
    ..g. lung, colon, stomach, liver and pancreatic) cells. Taken together, the two peptides derived from EphB6v might be appropriate targets for peptide-based specific immunotherapy for HLA-A2(+) patients with various cancers...
  33. ncbi request reprint Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients
    Hiroki Shomura
    Department of Immunology, School of Medicine, Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Eur J Cancer 40:1776-86. 2004
    ..These results may provide a scientific basis for the development of EGFR-based immunotherapy...
  34. ncbi request reprint Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses
    Takashi Mine
    Department of Immunology, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi Machi, Fukuoka, Kurume 830 0011, Japan
    Clin Cancer Res 10:929-37. 2004
    ..The aim of this study is to find a laboratory marker for overall survival in advanced cancer patients who were vaccinated with peptides based on pre-existing, peptide-specific CTL precursors in the circulation...
  35. ncbi request reprint Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients
    Shigetaka Suekane
    Department of Urology, Kurume University School of Medicine, Fukuoka 830 0011, Japan
    Cancer Sci 98:1965-8. 2007
    ..These results encourage further clinical trials of personalized peptide vaccinations...
  36. ncbi request reprint Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy
    Shigeru Yutani
    Department of Immunology, Kurume University School of Medicine, Japan
    Vaccine 25:7429-35. 2007
    ..Decrease of serum alanine aminotransferase and HCV-RNA levels after the 14th vaccination was also observed in five and three patients, respectively...
  37. ncbi request reprint A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33
    Satoko Matsueda
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, 830 0011, Japan
    Cancer Immunol Immunother 56:1359-66. 2007
    ..Among various genotypes of HCV, HCV1b is resistant to standard interferon therapy, and thus the development of new treatment modality is needed...
  38. ncbi request reprint New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients
    Akihisa Yao
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 62:233-42. 2005
    ..Therefore, PTHrP is a promising target in the treatment of metastatic prostate cancer...
  39. ncbi request reprint Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients
    Koichi Azuma
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Breast Cancer Res Treat 86:19-29. 2004
    ..These results may provide a scientific basis for new clinical trials of HER2/neu-peptide-based immunotherapy for breast cancer and also other epithelial cancer patients...
  40. ncbi request reprint A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients
    Satoko Matsueda
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 60:205-13. 2004
    ..We attempted to identify prostate stem cell antigen (PSCA)-derived peptides immunogenic in HLA-A24+ prostate cancer patients...
  41. ncbi request reprint Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, ururume 830 0011, Japan
    Cancer Sci 95:77-84. 2004
    ..We consider that the increase in cellular and humoral immune responses, and decrease in PSA level in some patients justify further development of peptide vaccination for metastatic HRPC patients...
  42. ncbi request reprint HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients
    Yuki Ishihara
    Department of Immunology, Kurume University School of Medicine, Kurume 830 0011, Japan
    Int J Oncol 24:967-75. 2004
    ....
  43. ncbi request reprint Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients
    Mingyue Jin
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka 830 0011, Japan
    Oncol Rep 19:1277-83. 2008
    ..Taken together, the two peptides derived from the variant of EphB6 might be appropriate targets for peptide-based specific immunotherapy to HLA-A24(+) patients with malignant glioma...
  44. ncbi request reprint A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients
    Shigeki Shichijo
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Eur J Cancer 41:1323-30. 2005
    ..Overall, this study provides new information about a colon cancer-related antigen that might be an appropriate target for specific immunotherapy in HLA-A2+ colon cancer patients...
  45. ncbi request reprint Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients
    Yi Wang
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Cell Immunol 241:38-46. 2006
    ..These results indicate that the identified three HCV2a peptides might be applicable to peptide-based immunotherapy for HLA-A24(+) HCV2a-infected patients...
  46. doi request reprint Personalized peptide vaccination in patients with refractory non-small cell lung cancer
    Koichi Yoshiyama
    Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Int J Oncol 40:1492-500. 2012
    ..Evaluation of the identified factors before or at an early stage of vaccination could be potentially useful for selecting NSCLC patients who would likely have better prognosis following PPV...
  47. doi request reprint Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
    Koichi Azuma
    Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Lung Cancer 64:326-33. 2009
    ....
  48. ncbi request reprint New epitope peptides derived from hepatitis C virus (HCV) 2a which have the capacity to induce cytotoxic T lymphocytes in HLA-A2+ HCV-infected patients
    Yi Wang
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka, Japan
    Microbiol Immunol 50:857-65. 2006
    ..These results indicate that the HCV2a 432-441, HCV2a 716-724, and HCV2a 2251-2260 peptides might be applicable for peptide-based immunotherapy of HLA-A2+ HCV2a-infected patients...
  49. ncbi request reprint Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Prostate 57:80-92. 2003
    ..To assess the safety and immune response of a peptide-based immunotherapy for patients with hormone-refractory prostate cancer, a phase I clinical trial was conducted...
  50. ncbi request reprint ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients
    Shigeki Shichijo
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Oncol Rep 13:907-13. 2005
    ..These results indicate that the ABCE1 and its peptides could be target molecules in specific immunotherapy for HLA-A2(+) colon cancer patients...
  51. ncbi request reprint Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles
    Takafumi Minami
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer Immunol Immunother 56:689-98. 2007
    ..These results indicate that these two SART3 peptides could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype(+) prostate cancer patients...
  52. doi request reprint Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
    Ryuji Takahashi
    Department of Surgery, Kurume University School of Medicine, Kurume, Japan
    Cancer Sci 104:1285-94. 2013
    ..Taken together, PPV could be feasible for the vast majority of refractory sarcoma patients because of the safety and higher rates of immunological responses regardless of the presence of different sarcoma subtypes and various HLA-types...
  53. doi request reprint Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy
    Masanori Noguchi
    Division of Clinical Research of the Research Center for Innovative Cancer Therapy, Kurume University School ofMedicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Prostate 72:834-45. 2012
    ..To explore cancer vaccine as a new treatment modality, we conducted a phase II study of personalized peptide vaccine (PPV) for DBC-resistant CRPC patients...
  54. ncbi request reprint Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination
    Masanori Noguchi
    Division of Clinical Research, Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
    Cancer Biol Ther 10:1266-79. 2010
    ..000282 and P = 0.00045). In contrast, CTL responses were not statistically different between the two groups. Both lymphocyte numbers and IgG response were thus suggested to be biomarkers of cancer vaccine for advanced cancer patients...
  55. ncbi request reprint Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients
    Mamoru Harada
    Department of Immunology, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Oncol Rep 17:629-36. 2007
    ..These results suggest the existence of KIF-reactive CTL precursors in glioma patients, and should facilitate the development of specific immunotherapies for malignant glioma...
  56. ncbi request reprint New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients
    Yukoh Itoh
    Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Oncol Rep 18:1231-7. 2007
    ..These results indicate that these EZH2 120-128 and EZH2 165-174 peptides could be promising candidates in peptide-based immunotherapy for HLA-A2+ prostate cancer patients...
  57. ncbi request reprint Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients
    Rika Ogata
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 60:273-81. 2004
    ..Antigens overexpressed in metastatic prostate cancer are appropriate targets in anti-cancer immunotherapy, and one candidate is the polycomb group protein enhancer of zeste homolog 2 (EZH2)...
  58. ncbi request reprint Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Prostate 67:933-42. 2007
    ..The purpose of this study was to determine the safety and immune responses of pre-operative personalized peptide vaccine for patients with localized prostate cancer...
  59. ncbi request reprint Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers
    Naotake Tsuda
    Departments of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    J Immunother 27:60-72. 2004
    ....
  60. ncbi request reprint Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen
    Kazuo Mochizuki
    Department of Gynecology, Kurume University, School of Medicine, Fukuoka 830 0011, Japan
    Int J Oncol 25:121-31. 2004
    ..These results suggest that the pre-designated regimen can elicit a primary immune response, but may incidentally suppress pre-existing immune responses...
  61. ncbi request reprint Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer
    Miho Hara
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 27:1371-9. 2005
    ..These results indicate that these HPV16-E6-derived peptides are good candidates in peptide-based immunotherapy for HLA-A24+ cervical cancer patients...
  62. ncbi request reprint Determination of thrombopoietin-derived peptides recognized by both cellular and humoral immunities in healthy donors and patients with thrombocytopenia
    Hiroko Takedatsu
    Department of Immunology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830 0011, Japan
    Stem Cells 23:975-82. 2005
    ..These results may provide new insights to gain a better understanding of autoimmune reactions to TPO...
  63. ncbi request reprint Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients
    Yoshiaki Maeda
    Department of Immunology, Kurume University School of Medicine, Kurume, Japan
    Int J Cancer 99:409-17. 2002
    ..Thus, these peptides might be appropriate molecules for use in the peptide-based specific immunotherapy of HLA-A2(+) patients with gastrointestinal cancers...
  64. ncbi request reprint A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation
    Naoya Hida
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Cancer Immunol Immunother 51:219-28. 2002
    ..Overall, this culture protocol can be useful in detecting and monitoring peptide-specific CTL precursors in the circulation in peptide-based immunotherapy against cancer...
  65. ncbi request reprint Immunological evaluation of vaccination of peptides derived from epithelial cancer-related antigens in two patients with hematological malignancy
    Hiroko Takedatsu
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 26:1605-12. 2005
    ..These results may provide a scientific rationale in use of epithelial cancer-related antigens for specific immunotherapy to patients with hematological malignancies...
  66. ncbi request reprint In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide
    Mamoru Harada
    Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    J Immunol 172:2659-67. 2004
    ....
  67. ncbi request reprint Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients
    Masanori Noguchi
    Department of Urology, Kurume University, Kurume, Japan
    Prostate 63:1-12. 2005
    ..The safety, toxicity, and immunological response of individualized peptide vaccination or human leukocyte antigen (HLA)-A24+ hormone refractory prostate cancer (HRPC) patients in combination with a low dose of estramustine were evaluated...
  68. doi request reprint A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Cancer Immunol Immunother 59:1001-9. 2010
    ..PPV plus low-dose EMP was associated with an improvement in PSA-based PFS as compared to the standard-dose EMP alone...
  69. ncbi request reprint Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients
    Kazuhiko Kobayashi
    Department of Immunology and Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Cancer Sci 94:622-7. 2003
    ..These results demonstrate that the PSMA 624-632 peptide could be an appropriate molecule for use in specific immunotherapy of HLA-A24(+) patients with prostate cancer...
  70. ncbi request reprint A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma
    S Nishizaka
    Department of Immunology, Kurume University School of Medicine, Japan
    Cancer Res 60:4830-7. 2000
    ..These results suggest that this gene product and peptide could be applicable to specific immunotherapy of lung cancer patients...
  71. ncbi request reprint Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer
    Nobuaki Suzuki
    Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Int J Cancer 98:45-50. 2002
    ..Positive peptide profiles varied among patients. These results may provide a scientific basis for a new kind of cancer immunotherapy, namely, a CTL precursor-oriented peptide vaccine, for pancreatic cancer patients...
  72. pmc Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients
    K Azuma
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Br J Cancer 89:1079-85. 2003
    ....
  73. ncbi request reprint Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site
    Koichi Azuma
    Department of Immunology, Kurume University School of Medicine, Kurume 830 0011, Japan
    Cancer Res 63:854-8. 2003
    ..These results provide a scientific basis for the development of p53-directed specific immunotherapy for HLA-B46(+) cancer patients...
  74. ncbi request reprint Expression of tumor-rejection antigens in gynecologic cancers
    S Tanaka
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Jpn J Cancer Res 91:1177-84. 2000
    ..Therefore, these four antigens and their peptides, including SART3 peptides, would be appropriate molecules for use in specific immunotherapy of HLA-A24(+) gynecologic cancer patients...
  75. ncbi request reprint IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients
    N Kawamoto
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan
    Tissue Antigens 61:352-61. 2003
    ..This information may provide new insight into the immune-mechanisms of elevated auto-reactivity of AD patients...
  76. ncbi request reprint [HLA-restricted cancer-specific killer T cells]
    Mamoru Harada
    Department of Immunology, Kurume University School of Medicine
    Nihon Rinsho 63:579-84. 2005
  77. ncbi request reprint Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas
    S Yutani
    Department of Immunology, Kurume University School of Medicine, Kurume 830-0011, Japan
    Oncol Rep 8:369-72. 2001
    ..These results suggest that the SART1259 antigen could be an appropriate target molecule for use in specific immunotherapy of HCC patients...
  78. ncbi request reprint Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes
    M Kikuchi
    Cancer Vaccine Development Division of Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Japan
    Int J Cancer 81:459-66. 1999
    ..The SART-1(690-698) peptide could thus be useful for specific immunotherapy of HLA-A24+ cancer patients...
  79. pmc A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes
    S Shichijo
    Department of Immunology, Kurume University School of Medicine, Kurume, Japan
    J Exp Med 187:277-88. 1998
    ..The 43-kD protein and this nonapeptide (KGSGKMKTE) may be useful for the specific immunotherapy of HLA-A2601(+) epithelial cancer patients...
  80. ncbi request reprint Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients
    D Yang
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Japan
    Cancer Res 59:4056-63. 1999
    ..These peptides may be useful in specific immunotherapy for HLA-A24+ cancer patients with various histological types...
  81. pmc Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients
    Y Suefuji
    Department of Oral and Maxillofacial Surgery, Kurume University School of Medicine, Fukuoka, Japan
    Br J Cancer 84:915-9. 2001
    ..Therefore, the SART3 antigen and its peptides could be an appropriate molecule for use in specific immunotherapy of the majority of HLA-A24-positive breast cancer patients...
  82. ncbi request reprint T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma
    Wataru Kumamaru
    Department of Oral and Maxillofacial Surgery, Graduate School of Dental Science, Kyushu University, Fukuoka, Japan
    Int J Cancer 108:686-95. 2004
    ..The identification of the unique TCR Vbeta genes used by SART-1(259)-specific CTLs should help to improve the diagnosis of the specific immune response in patients with SART-1(259) (+) cancers, especially during anticancer immunotherapy...
  83. ncbi request reprint [Peptide vaccination therapy for malignant glioma]
    Ryuya Yamanaka
    Research Center of Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830 0011, Japan
    Brain Nerve 59:251-61. 2007
    ..Peptide-based therapy of glioma seems to be safe and without major side effects. Biotherapy for malignant glioma with peptide will open a novel reality now...
  84. ncbi request reprint Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases
    N Imai
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Int J Cancer 94:237-42. 2001
    ..Overall, the Lck(246-254) and Lck(422-430) peptides could be useful for specific immunotherapy of HLA-A2(+) cancer patients, especially with distant metastases...
  85. ncbi request reprint Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients
    Shinya Ohkouchi
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Asahi machi, Kurume, Japan
    Eur J Immunol 33:2964-73. 2003
    ..be appropriate for use in peptide-based immunotherapy for relatively large numbers of cancer patients throughout the world, given that 34% of Japanese, 27% of Chinese, and 13% of Caucasians express either HLA-B52 or HLA-B62 molecules..
  86. ncbi request reprint New type of natural antibodies reactive to cytotoxic T lymphocyte-directed cancer vaccine peptides
    Kunie Fukuda
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Japan
    Immunobiology 209:245-53. 2004
    ..The Abs showed catalytic activity upon hydrogen peroxide (H2O2) production. These results suggest the existence of a novel type of natural Ab that is reactive to cancer vaccine peptides...
  87. doi request reprint An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles
    Yasunobu Terasaki
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Cancer Immunol Immunother 58:1877-85. 2009
    ..These results suggest that this peptide could be widely applicable as a peptide vaccine for HLA-A3 supertype-, HLA-A2-, and -A24-positive cancer patients...
  88. ncbi request reprint Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients
    Yamei Niu
    Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer Sci 100:2167-74. 2009
    ..These results may provide novel information for the development of a peptide-based cancer vaccine for HLA-A26-positive patients...
  89. ncbi request reprint Expression of the SART1 tumor-rejection antigen in human osteosarcomas
    H Ishida
    Departments of Orthopaedic Surgery and Immunology, Kurume University School of Medicine, Japan
    Int J Oncol 17:29-32. 2000
    ..These results raise a possibility that the SART1259 would be an appropriate molecule for use in specific immunotherapy of approximately one-third of HLA-A24+ patients with osteosarcoma and MFH...
  90. ncbi request reprint Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides
    N Tsuda
    Department of Immunology, School of Medicine, Kurume University, Japan
    J Orthop Res 19:346-51. 2001
    ..These results suggest that the SART3 protein and its derived peptides could be molecules appropriate for use in specific immunotherapies for approximately 60% of HLA-A24+ patients with osteosarcoma or malignant fibrous histiocytosis...
  91. ncbi request reprint Molecular basis of T cell-mediated recognition of pancreatic cancer cells
    M Ito
    Department of Immunology, Kurume University School of Medicine, Japan
    Cancer Res 61:2038-46. 2001
    ..These results should provide a scientific basis for the development of specific immunotherapy for pancreatic and colon cancer patients...
  92. ncbi request reprint CDw108 expression during T-cell development
    T Mine
    Kurume University Research Center for Innovative Cancer Therapy, Department of Surgery, Kurume University School of Medicine, Japan
    Tissue Antigens 55:429-36. 2000
    ..These results suggest the contribution of CDw108 in T-cell development, especially in the stage of positive selection in the thymus...
  93. pmc Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients
    Y Maeda
    Department of Immunology, Kurume University, 67 Asahi Machi, Kurume, 830 0011, Japan
    Br J Cancer 87:796-804. 2002
    ..These results may provide a scientific basis for the development of a new approach to cancer immunotherapy, e.g.) cytotoxic T lymphocytes-precursor-oriented peptide vaccine...
  94. doi request reprint Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients
    Masayasu Naito
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 68:1753-62. 2008
    ..To evaluate the immunological responses of personalized peptide vaccination combined with low-dose glucocorticoids for advanced hormone refractory prostate cancer (HRPC) patients (pts)...
  95. doi request reprint A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Prostate 71:470-9. 2011
    ..To evaluate the safety, tolerability, immune response, and antitumor activity of a combination of personalized peptide vaccination (PPV) and estramustine phosphate (EMP) in patients with castration-resistant prostate cancer (CRPC)...
  96. doi request reprint Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme
    Mizuhiko Terasaki
    Department of Neurosurgery, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    J Clin Oncol 29:337-44. 2011
    ..We present the results of a phase I trial of 14 kinds of vaccine candidates (ITK-1) in patients with recurrent or progressive glioblastoma multiforme (GBM)...
  97. ncbi request reprint Peptide-based immunotherapeutic approaches to glioma: a review
    Ryuya Yamanaka
    Kurume University School of Medicine, Research Center of Innovative Cancer Therapy, Asahimachi 67, Kurume, Fukuoka 830 0011, Japan
    Expert Opin Biol Ther 7:645-9. 2007
    ..Now, peptide-based immunotherapy could be a new treatment modality for patients with brain tumors...
  98. ncbi request reprint Development of a new diagnostic tool for pancreatic cancer: simultaneous measurement of antibodies against peptides recognized by cytotoxic T lymphocytes
    Masahiro Tanaka
    Department of Immunology, Kurume University School of Medicine, Kurume, Japan
    Kurume Med J 53:63-70. 2006
    ..These results suggest that the simultaneous measurement of IgGs reactive to these peptides could potentially be useful as a new diagnostic tool to screen for pancreatic cancer...
  99. ncbi request reprint Target molecules in specific immunotherapy against prostate cancer
    Mamoru Harada
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Int J Clin Oncol 8:193-9. 2003
    ....
  100. ncbi request reprint Elevation of serum MAGE-4 protein levels and prediction of hepatocellular carcinogenesis in patients with liver cirrhosis
    Shigeru Yutani
    Second Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Jpn J Cancer Res 93:453-8. 2002
    ..These results indicate that elevated serum MAGE-4 protein levels can be a predictive marker of hepatocellular carcinogenesis in cirrhotic patients, thereby enabling us to treat patients at an earlier stage...
  101. ncbi request reprint Expression of tumor rejection antigens in colorectal carcinomas
    Teruo Sasatomi
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer 94:1636-41. 2002
    ..The current study investigated these antigens to explore a potential molecule for specific immunotherapy for colorectal carcinoma patients...